Display options
Cite
Fromtling RA. Human mycoses and advances in antifungal therapy. Drug News Perspect. 2001;14(3):181-92
Fromtling, R. A. (2001). Human mycoses and advances in antifungal therapy. Drug news & perspectives, 14(3), 181-92.
Fromtling, R A. "Human mycoses and advances in antifungal therapy." Drug news & perspectives vol. 14,3 (2001): 181-92.
Fromtling RA. Human mycoses and advances in antifungal therapy. Drug News Perspect. 2001 Apr;14(3):181-92. PMID: 12819825.
Copy Download .nbib Format: NLM
Share it on

Drug News Perspect. 2001 Apr;14(3):181-92.

Human mycoses and advances in antifungal therapy.

Drug news & perspectives

R A Fromtling

Affiliations

  1. Merck Research Laboratories, Rahway, NJ 07065-0900, USA.

PMID: 12819825

Abstract

The 11th Focus on Fungal Infections meeting was held in Washington, D.C., U.S.A., March 1416, 2001. At the conference, there were well-attended sessions that focused on the pathogenesis and therapy of fungal disease. This report focuses on new information on fungal incidence and pathogenesis as well as on the in vitro and clinical experience of established antifungal drugs (fluconazole, itraconazole, amphotericin B, liposomal formulations of amphotericin B, terbinafine) and the newer antifungal compounds approved for use (e.g., caspofungin) and in development (the new-generation azoles: voriconazole, posaconazole, ravuconazole, and the candins, micafungin and anidulafungin).

(c) 2001 Prous Science. All rights reserved.

Publication Types